Indiana Attorney General Todd Rokita is accusing Eli Lilly of conspiring with its competitors to artifically raise the price of insulin.

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income stories. The company's rapid growth, aggressive capital returns, and accelerating dividend policy are reshaping how I view big pharma in 2026,

Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.

Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.

A key to the pill's success will be attracting cash-paying consumers who cannot obtain insurance coverage, a stark shift from the dominant business model.

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the pharmaceutical giant has been making a push in oncology. And why it is building an artificial intelligence supercomputer that could help it develop medicines much faster and at lower costs.